Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00662636 · ClinicalTrials.gov registry record · Phase 1
Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00662636: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00662636 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00662636, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
RATIONALE: Dasatinib and lapatinib ditoslylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of dasatinib and lapatinib ditoslylate when given together in treating patients with advanced solid tumors that cannot be removed by surgery.
Interventions
- OTHER laboratory biomarker analysis
- DRUG dasatinib
- OTHER pharmacological study
- DRUG lapatinib ditosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2008-08 |
| Est. Completion | 2014-12-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00662636
The ClinicalTrials.gov registry entry for NCT00662636 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00662636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00662636 about?
NCT00662636 is a clinical study titled "Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery". RATIONALE: Dasatinib and lapatinib ditoslylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of dasatinib and lapatinib ditoslylate when given together in treating patients with advan...
What is the current status of trial NCT00662636?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2008-08. Estimated completion is 2014-12-18.
What interventions are being tested in trial NCT00662636?
The interventions under investigation include: laboratory biomarker analysis (OTHER), dasatinib (DRUG), pharmacological study (OTHER), lapatinib ditosylate (DRUG).
Who is sponsoring clinical trial NCT00662636?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.